MetLife wins epic battle with federal regulators
6 Types of Financial Advisor
So, Why Else Do the Pundits Hate Annuity Commissions?
The IRS and the Treasury Department must issue immediate guidance on 39 areas of the Tax Cuts and Jobs Act to clarify “entity structure, retirement, wealth transfer and a vast number of other tax planning issues,” Annette Nellen, the American Institute of Certified Public Accountants’ Tax Executive Committee chairwoman, urged the IRS and Treasury on Monday.
In her letter to David Kautter, assistant secretary for Treasury’s Tax Policy Department, and William Paul, the IRS’ deputy chief counsel, Kellen said that the two entities must shed light on various areas to help taxpayers and practitioners comply with their 2017 tax obligations.
The IRS did not return a call for comment by press time.
Nellen’s letter highlights three areas of particular concern:
Nellen further explained that under Section 199A(d)(2), Deduction for Qualified Business Income, more guidance is needed on the meaning of specified service trade or business as defined in the section “namely, any trade or business involving the performance of services in the fields of health, law, accounting, actuarial science, performing arts, consulting, athletics, financial services, brokerage services, or any trade or business where the principal asset of such trade or business is the reputation or skill of 1 or more of its employees or owners, or any trade or business which involves the performance of services that consist of investing and investment management, trading, or dealing in securities, partnership interests or commodities.”
Top 5 Stocks To Buy For 2018: NxStage Medical, Inc.(NXTM)
- [By Dan Caplinger]
For nine months now, investors in NxStage Medical (NASDAQ:NXTM) have looked forward to the future. Having received and accepted a bid from Fresenius Medical Care (NYSE:FMS) last August to purchase the company for $30 per share in cash, NxStage has seen a lot more volatility in its stock than most acquisition targets. With a key deadline approaching within the next three months, it’s hard not to be anxious about whether the deal will actually go through.
Top 5 Stocks To Buy For 2018: Celyad SA(CYAD)
- [By Lisa Levin] Gainers
Genprex, Inc. (NASDAQ: GNPX) jumped 46.7 percent to $16.1331. The low-float small-cap clinical stage gene therapy company saw its stock rally nearly 150 percent from Monday through Thursday. Formal news hasn't been announced this week that would support a triple-digit percentage rally (including more than 200 percent at one point on Thursday) but the quiet period following its initial public offering will expire on May 8.
Celyad SA (NASDAQ: CYAD) shares gained 24.7 percent to $36.17. Celyad reported the publication of THINK study case report of CYAD-01 Induced Complete Remission in relapsed/refractory AML patient in haematologica.
DMC Global Inc. (NASDAQ: BOOM) shares jumped 23.2 percent to $39.00 after the company reported upbeat Q1 results and issued upbeat Q2 guidance.
eHealth, Inc. (NASDAQ: EHTH) gained 21.8 percent to $19.58 as the company posted upbeat Q1 results.
Enova International, Inc. (NYSE: ENVA) climbed 20.4 percent to $27.20 following Q1 results.
SVB Financial Group (NASDAQ: SIVB) shares jumped 18.2 percent to $304.135 following strong quarterly results.
Knowles Corporation (NYSE: KN) gained 13.9 percent to $12.70 as the company reported Q1 results.
Zymeworks Inc. (NYSE: ZYME) gained 13.8 percent to $17.36.
Cocrystal Pharma, Inc. (NASDAQ: COCP) rose 11.8 percent to $2.336 after declining 25.09 percent on Thursday.
ImmunoGen, Inc. (NASDAQ: IMGN) shares surged 11.7 percent to $11.75 after the company announced 'successful completion of interim analysis' for FORWARD I Phase 3 mirvetuximab soravtansine trial.
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) gained 9.5 percent to $12.70.
Expedia Group, Inc. (NASDAQ: EXPE) shares rose 8.5 percent to $115.3801 after the company reported stronger-than-expected earnings for its first quarter on Thursday.
Sprint Corporation (NYSE: S) shares rose 8.3 percent to $6.50. The stock moved higher after a Reuters report suggested ongoing merger talks with T-M
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Verastem, Inc. (NASDAQ: VSTM) fell 9.7 percent to $4.73 in pre-market trading after announcing a $35 million common stock offering.
Evolus, Inc. (NASDAQ: EOLS) shares fell 8 percent to $13.48 in pre-market trading ahead of regulatory update at 8:30 a.m. ET.
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) fell 6.5 percent to $2.01 in pre-market trading after climbing 10.50 percent on Tuesday.
Purple Innovation, Inc. (NASDAQ: PRPL) shares fell 5.8 percent to $9.36 in pre-market trading after reporting Q1 results.
Blink Charging Co. (NASDAQ: BLNK) fell 5.7 percent to $5.15 in pre-market trading after declining 5.04 percent on Tuesday.
RYB Education, Inc. (NYSE: RYB) shares fell 5 percent to $16.39 in pre-market trading following Q1 results.
Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares fell 4.4 percent to $4.30 in pre-market trading after rising 40.62 percent on Tuesday.
Arbor Realty Trust, Inc. (NYSE: ABR) fell 4.4 percent to $8.92 in pre-market trading after announcing a 5.5 million share common stock offering.
Daxor Corporation (NYSE: DXR) fell 4.1 percent to $7.32 in pre-market trading.
Ormat Technologies, Inc. (NYSE: ORA) shares fell 3.8 percent to $51.03 in pre-market trading after the company announced plans to restate its Q2, Q3, Q4 and FY 2017 financial statements.
Canadian Solar Inc. (NASDAQ: CSIQ) fell 3.5 percent to $16.20 in pre-market trading after reporting Q1 results.
CELYAD SA/ADR (NASDAQ: CYAD) shares fell 3.3 percent to $29.70 in pre-market trading after the company reported launch of 1.8 million share offering
- [By Lisa Levin]
Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis, Inc. (NASDAQ: ABAX) for $83 per share in cash.
Boot Barn Holdings Inc (NYSE: BOOT) reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
CELYAD SA/ADR (NASDAQ: CYAD) reported launch of 1.8 million share offering.
Verastem Inc (NASDAQ: VSTM) shares dropped 12 percent in pre-market trading after announcing a $35 million common stock offering.
Top 5 Stocks To Buy For 2018: Rite Aid Corporation(RAD)
- [By ]
“Alexa, order me my Lipitor” are five words that could prove financially devastating to pharmacies such as Walgreens Boots Alliance (WBA) , CVS Health (CVS) and Rite Aid (RAD) .
- [By Chris Lange]
Rite Aid Corp. (NYSE: RAD) fiscal third-quarter report is scheduled for late on Wednesday. Consensus estimates are calling for a net loss of $0.02 per share and $7.45 billion in revenue. The shares closed trading at $1.97 apiece on Friday. The consensus price target is $2.11, and the 52-week trading range is $1.38 to $8.77.
- [By Peter Graham]
Smallcap retail drugstore stock Rite Aid Corporation (NYSE: RAD) reported Q3 2018 earnings after the market closed Wednesday as the Company struggles with falling profitsin its pharmacy business as increases in branded drug prices have slowed while reimbursement pressure for generics has increased.
Top 5 Stocks To Buy For 2018: Core Laboratories N.V.(CLB)
- [By Taylor Muckerman]
Muckerman: I can go. That’ll work. One company I’m paying close attention to is Core Labs (NYSE:CLB). They’re based out of the Netherlands, but they have their U.S., maybe global, headquarters in Houston. This is a premier company that’s involved in reservoir description and enhancement services. So, when you’re looking at a well, they can basically recreate the well in their lab and tell you exactly what kind of fluid, what kind of proppants, what kind of chemicals, what kind of pressure. They can tell you exactly how to get the most bang for your buck. It’s not cheap, but it’s worth it in the long run. And this company is just continually buying back shares with their money. They generate tons of free cash flow.
- [By Matthew DiLallo]
That trend was one of the central themes on the first-quarter conference call of oil-field technology company Core Labs (NYSE:CLB), where CEO David Demshur provided his take for why things are different in the oil market this time around.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Core Laboratories (CLB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Maxx Chatsko]
Shares of oilfield services company Core Laboratories (NYSE:CLB) have pinballed around in the last three years to yield a total return of 0.9% in that span. That’s not exactly the type of consistency investors are after.
- [By Shane Hupp]
Mar Vista Investment Partners LLC decreased its holdings in shares of Core Laboratories (NYSE:CLB) by 4.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 368,372 shares of the oil and gas company’s stock after selling 16,913 shares during the period. Core Laboratories makes up approximately 1.6% of Mar Vista Investment Partners LLC’s investment portfolio, making the stock its 28th largest holding. Mar Vista Investment Partners LLC’s holdings in Core Laboratories were worth $39,865,000 at the end of the most recent quarter.
- [By ]
America’s oil renaissance is powered almost exclusively by technology, as companies like Schlumberger (SLB) and Core Labs (CLB) are breathing new life into once forgotten wells. Nucor (NUE) has a similar leadership position in the steel industry thanks to technology, and that company will only benefit more that President Trump’s tariffs put the market on a more level playing field.
Top 5 Stocks To Buy For 2018: Ventas, Inc.(VTR)
- [By Reuben Gregg Brewer]
My timing, however, isn’t always so good, and I sometimes get in too early. But owning a great dividend-paying company at a fair price is better than owning a bad company at any price. Which is why I’m happy to have bought U.S. utility giant The Southern Company (NYSE:SO) and healthcare real estate investment trust (REIT) Ventas, Inc. (NYSE:VTR). And I’ll be just as happy if they fall further from here.
- [By Joseph Griffin]
Virginia Retirement Systems ET AL boosted its position in Ventas (NYSE:VTR) by 10.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 204,186 shares of the real estate investment trust’s stock after acquiring an additional 19,200 shares during the quarter. Virginia Retirement Systems ET AL owned 0.06% of Ventas worth $10,113,000 as of its most recent filing with the Securities & Exchange Commission.